News

TP53 Alterations Predict Rapid Treatment Resistant Evolution in Patients With EFGR-Mutated NSCLC

08/09/2022

Study findings reveal TP53 alterations were associated with rapid progression of treatment resistance evolution regardless of treatment mechanism in patients with EFGR-mutated NSCLC.

Study findings reveal TP53...

08/09/2022

Oncology

News

Amivantamab Associated With Improved Outcomes vs Real-World Therapies in EGFR-Mutated NSCLC

07/07/2022

Janelle Bradley ;

Among patients with EGFR-mutated advanced NSCLC whose disease progressed after platinum-based chemotherapy, treatment with amivantamab is associated with improved outcomes vs real-world therapies, according to a recent study.

Among patients with EGFR-mutated...

07/07/2022

Oncology

News

Aumolertinib vs Gefitinib as First-Line Treatment for Patients With EFGR-Mutated NSCLC

07/06/2022

Derek Cowsert ;

Study findings reveal first-line treatment with aumolertinib was associated with improved survival outcomes compared to gefitinib in patients with EFGR-mutated NSCLC.

Study findings reveal first-line...

07/06/2022

Oncology

News

First-Line Bevacizumab Plus Erlotinib Prolongs PFS in EGFR-Mutated Advanced NSCLC: BEVERLY Trial

06/20/2022

Yvette C. Terrie , BS Pharm, RPh;

Bevacizumab added to erlotinib improved PFS among Italian patients with EGFR-mutated NSCLC, according to results from the phase 3 BEVERLY trial.

Bevacizumab added to erlotinib...

06/20/2022

Oncology

News

Osimertinib Plus Bevacizumab Fails to Improve PFS Among Patients With NSCLC Harboring EGFR Mutations

06/20/2022

Yvette C. Terrie , BS Pharm, RPh;

In a phase 2 study, osimertinib plus bevacizumab failed to improve PFS vs osimertinib monotherapy for previously untreated patients with advanced nonsquamous NSCLC harboring EGFR mutations.

In a phase 2 study, osimertinib...

06/20/2022

Oncology

News

First-Line Treatment With TKIs Associated With Improved Survival in EGFR-Positive NSCLC

05/05/2022

John Otrompke , BA, JD;

In the 7 years following the release of treatment guidelines recommending TKIs for EGFR-positive NSCLC, OS has almost doubled among female patients younger than 50 years, according to a population-based study from the Netherlands.

In the 7 years following the...

05/05/2022

Oncology

News

What is the Preferred Treatment Option for Patients with NSCLC Harboring Uncommon EGFR Mutations?

05/05/2022

John Otrompke , BA, JD;

Study findings suggest EGFR TKIs are the preferred treatment option for patients with NSCLC and uncommon EGFR mutations in the real-world setting.

Study findings suggest EGFR TKIs...

05/05/2022

Oncology

News

First-Line EGFR Inhibition Improves Overall Survival in EGFR–Amplified Gastroesophageal Adenocarcinoma

05/05/2022

John Otrompke , BA, JD;

Patients with EGFR–amplified gastroesophageal adenocarcinoma derive significant benefit from EGFR inhibition in the first-line setting, according to findings from a recent analysis.

Patients with EGFR–amplified...

05/05/2022

Oncology

News

Debates and Updates of VEGF Superiority in RAS Wild-Type CRC

03/26/2022

Cathy Eng, MD, FACP, FASCO, argued for VEGF therapy versus anti-EGFR inhibition in a debate with Dr Kasi at the 2022 GDU GI conference in New York, NY.

Cathy Eng, MD, FACP, FASCO,...

03/26/2022

Oncology

News

First-Line Treatment in Left-Sided, RAS/BRAF Wild-Type Metastatic Colorectal Cancer: EGFR Inhibitors vs VEGF Inhibitors

03/26/2022

Alex Stoia ;

Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.

Pashtoon M. Kasi, MD, MS, argued...

03/26/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology